Fimepinostat in Treating Brain Tumors in Children and Young Adults

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

August 31, 2027

Conditions
Diffuse Intrinsic Pontine GliomaRecurrent Anaplastic AstrocytomaRecurrent GlioblastomaRecurrent Malignant GliomaRecurrent Medulloblastoma
Interventions
DRUG

Fimepinostat

Fimepinostat capsules

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (19)

8032

The University Children's Hospital in Zurich, Zurich

19146

Children's Hospital of Philadelphia (CHOP), Philadelphia

20010

Children's National Medical Center, Washington D.C.

21231

Johns Hopkins Hospital, Baltimore

32611

University of Florida, Gainesville

38105

St. Jude Children's Research Hospital, Memphis

43205

Nationwide Children's, Columbus

48109

University of Michigan Hospital, Ann Arbor

55404

Children's Minnesota Research Institute, Minneapolis

60611

Lurie Children's Hospital of Chicago, Chicago

63110

Washington University in St Louis, St Louis

77030

Texas Children's Hospital, Houston

84113

University of Utah, Children's Primary, Salt Lake City

90027

Children's Hospital Los Angeles (CHLA), Los Angeles

92123

Rady Children's Hospital, San Diego

94143

University of California, San Francisco, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Pediatric Neuro-Oncology Consortium

OTHER

collaborator

Cannonball Kids' Cancer Foundation

OTHER

collaborator

Curis, Inc.

INDUSTRY

lead

Sabine Mueller, MD, PhD

OTHER